TNFRSF8 negative

Overall, EPOCH was well tolerated with high response rates in first line and R/R setting.

These entities are currently treated similarly with CHOP or CHOEP for CD30-negative diseases or brentuximab vedotin plus CHP for CD30-positive diseases, followed by consolidation with autologous stem cell transplant in first remission...Although current treatment strategies lump most disease entities together, future treatment will include distinct strategies for each disease subtype that optimizes therapy for individuals. This movement towards individualized therapy will ultimately lead to dramatic improvements in prognosis for patients with PTCL.

P1, N=18, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center

Following discussions with Henry Ford Lymphoma Tumor Board, patient was treated with six cycles of R-CHOP, where follow-up imaging indicated remission of her lymphoma. ConclusionThis represents an extraordinary first report of HGBL NOS manifesting as an isolated primary hepatic lymphoma in the complete absence of clinical symptoms. The significance of this case lies in its atypical extra-nodal site of involvement and total absence of clinical symptoms and serological markers, underscoring the unfulfilled need to further describe this enigmatic entity.

These results indicate that BCL11b may be involved in CD30 differentiation and PTCL prognosis. The detection and targeting of BCL11b and CD30 may provide new strategies for the treatment and classification of PTCL.

We provide a framework for unbiased, multi-dimensional target screening and highlight the functional relevance of the immunosuppressive CTLA-4-CD86 axis in HL. Our results further emphasize the role of anti-CD86 - targeted therapies either as an alternative to or in conjunction with anti-CD30-based therapies in HL.

In CD30-negative ROIs in MF-LCT compared to cALCL, memory B (p=0.021), plasma (p=0.023), and CD8 memory T (p=0.001) cells significantly decreased whereas regulatory T cells (p=0.024) increased. Predomination of ECM remodeling pathways and immunosuppressive microenvironment in MF-LCT indicates pathophysiological differences from MF-LCT and cALCL.

P2, N=58, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025

KEY MESSAGE: The importance of acknowledging the evolution of this pathology is to recognize it in its early stages. Additionally, the peripheral blood flow cytometry categorizes the patient as class B1 or “pre-Sézary syndrome”